The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

The breakup between Novo Nordisk and Hims & Hers remains acrimonious. Recent remarks highlight the competition facing Novo ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

Novo Nordisk has cut ties with Hims & Hers Health, alleging that the latter company has engaged in deceptive marketing ...

The timing is also interesting. GLP-1s are Novo Nordisk's biggest and fastest-growing revenue stream, and competition is heating up. Eli Lilly's Zepbound is gaining traction, compounded access is ...

Hims & Hers stock plunged around 30% on Monday after drugmaker Novo Nordisk abruptly ended a month-long collaboration to make ...

Despite Novo Nordisk (NVO) recently ending a partnership with Hims & Hers Health (NYSE:HIMS) to distribute its weight-loss ...

Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...